Clene to Provide CNM-Au8® ALS Program Update

Rhea-AI Summary

Clene (Nasdaq: CLNN) will host a CNM-Au8 ALS program update webcast and investor call on December 3, 2025 at 8:30 a.m. ET.

Presenters include Rob Etherington (CEO and President), Dr. Ben Greenberg (Head of Medical), Michael Hotchkin (Chief Development Officer) and a key opinion leader. The live webcast link and dial‑in numbers are provided for U.S. and international participants, and an archived webcast will be available on the company website approximately two hours after the event.

News Market Reaction

-3.14% 37.1x vol

39 alerts

-3.14% News Effect

+33.3% Peak Tracked

-27.8% Trough Tracked

-$3M Valuation Impact

$107M Market Cap

37.1x Rel. Volume

On the day this news was published, CLNN declined 3.14%, reflecting a moderate negative market reaction. Argus tracked a peak move of +33.3% during that session. Argus tracked a trough of -27.8% from its starting point during tracking. Our momentum scanner triggered 39 alerts that day, indicating elevated trading interest and price volatility. This price movement removed approximately $3M from the company's valuation, bringing the market cap to $107M at that time. Trading volume was exceptionally heavy at 37.1x the daily average, suggesting significant selling pressure.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Webcast date: December 3, 2025 Webcast time: 8:30 a.m. ET

2 metrics

Webcast date December 3, 2025 CNM-Au8 ALS program update webcast

Webcast time 8:30 a.m. ET Start time for ALS program update call

Market Reality Check

Price: $5.05 Vol: Volume 124,002 is below 2...

low vol

$5.05 Last Close

Volume Volume 124,002 is below 20-day average of 321,987 (relative volume 0.39). low

Technical Shares at $6.88 are trading above the $5.24 200-day moving average.

Peers on Argus

Peers show mixed moves, with ATPC down 18.51% and PAVS up 9.28%, indicating stoc...

1 Up 1 Down

Peers show mixed moves, with ATPC down 18.51% and PAVS up 9.28%, indicating stock-specific factors rather than a broad sector move.

Historical Context

5 past events · Latest: Dec 09 (Neutral)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Dec 09	Investor conference	Neutral	+6.3%	Virtual corporate update at the Emerging Growth Conference with webcast access.
Dec 03	Clinical data update	Positive	-22.0%	Statistically significant ALS biomarker data supporting an accelerated approval pathway.
Dec 02	Program webcast notice	Neutral	-3.1%	Announcement of CNM-Au8 ALS program update webcast and investor call details.
Nov 20	Investor conference	Neutral	+1.3%	Participation in Benchmark one-on-one investor conference and scheduled meetings.
Nov 13	Earnings and outlook	Negative	-22.4%	Q3 2025 results highlighting losses, low cash, and going-concern language.

Pattern Detected

Large positive ALS data and negative financial updates both saw sharp selloffs, while conference and webcast notices tended to have smaller, mixed reactions.

Recent Company History

Over recent months, Clene issued several ALS‑focused updates and financing disclosures. A webcast notice on Dec 2, 2025 and later a corporate update conference mainly served communication purposes with modest price shifts around -3.14% and +6.31%. By contrast, statistically significant ALS biomarker data on Dec 3, 2025 and Q3 2025 results on Nov 13, 2025 were followed by steep declines of -22.03% and -22.42%. Investor conference participation on Nov 20, 2025 had only a mild positive impact.

Regulatory & Risk Context

Active S-3 Shelf

Shelf Active

Active S-3 Shelf Registration 2025-09-05

The company has an active S-3 shelf filed on 2025-09-05 with recent usage evidenced by 424B5 prospectus supplements on 2025-09-05 and 2025-10-17, indicating an established mechanism for issuing additional securities.

Market Pulse Summary

This announcement centered on logistics for a CNM-Au8 ALS program update webcast on December 3, 2025...

Analysis

This announcement centered on logistics for a CNM-Au8 ALS program update webcast on December 3, 2025, outlining timing, access links, and presenters. Recent history shows that larger moves tended to follow substantive ALS biomarker data and quarterly financials, while conference and webcast notices had smaller impacts. Investors reviewing such events may focus on future clinical milestones, funding disclosures, and any subsequent use of the existing S-3 registration to assess risk.

Key Terms

amyotrophic lateral sclerosis (ALS), ALS, multiple sclerosis (MS), MS, +3 more

7 terms

amyotrophic lateral sclerosis (ALS) medical

"neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis"

Amyotrophic lateral sclerosis (ALS) is a progressive neurological disease that damages nerve cells responsible for controlling voluntary muscles, leading to muscle weakness, loss of movement, and eventually paralysis. It matters to investors because health-related research, treatments, and biotech companies working on ALS can influence stock markets and create opportunities or risks within the healthcare sector.

ALS medical

"provide an update on its CNM-Au8 program in ALS, and to host an investor call"

Amyotrophic lateral sclerosis (ALS) is a progressive neurological disease that damages the nerve cells controlling muscles, gradually causing weakness, loss of movement and difficulty breathing — similar to the body’s wiring slowly failing. For investors, ALS matters because research progress, clinical trial results, regulatory approvals or setbacks can dramatically affect the value of companies developing treatments, patient-care markets and related healthcare services.

multiple sclerosis (MS) medical

"neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS)"

Multiple sclerosis (MS) is a chronic neurological disease in which the immune system damages the insulating sheath around nerve fibers in the brain and spinal cord, interrupting electrical signals and causing symptoms like weakness, numbness, vision problems, and fatigue. Investors pay attention because MS drives long-term demand for therapies, clinical trial outcomes and regulatory approvals can sharply change a drugmaker’s revenue prospects, and advances or setbacks in treatment options affect long-term healthcare costs and company valuations.

MS medical

"neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS)"

Multiple sclerosis is a chronic neurological disease in which the immune system damages the protective coating around nerve fibers, like frayed insulation on electrical wires, disrupting signals between the brain and body. Investors care because treatments, clinical trial results, regulatory approvals, and long-term care costs linked to the disease can materially affect the financial prospects of drugmakers, medical-device companies, and healthcare service providers.

nanomedicine medical

"its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical"

Nanomedicine uses extremely tiny engineered materials and devices — often measured in billionths of a meter — to diagnose, monitor, or treat disease, for example by delivering drugs directly to specific cells or enhancing imaging. For investors it signals a high-tech approach with the potential for more effective therapies, smaller doses, and new product categories, but also brings specialized manufacturing, regulatory scrutiny, and research risk that can affect development timelines and returns.

webcast technical

"to host an investor call and webcast at 8:30 am ET on Wednesday"

A webcast is a live or recorded online event where people watch or listen to presentations, announcements, or performances through the internet. It’s like a TV broadcast but over the internet, allowing viewers from anywhere to tune in in real time or later. Webcasts are important because they let companies share information quickly and widely with audiences around the world.

KOL technical

"Chief Development Officer and a KOLDate: December 3, 2025Start Time"

A KOL, or key opinion leader, is a trusted expert—often a leading physician, researcher, or specialist—whose views influence peers, clinical practice, and industry adoption of medical products or treatments. For investors, KOL endorsements or criticisms can sway adoption rates, regulatory perceptions, and market confidence much like a respected critic can affect demand for a new product, so monitoring KOL sentiment helps gauge commercial and clinical prospects.

AI-generated analysis. Not financial advice.

Webcast set for 8:30 a.m. ET on December 3rd

SALT LAKE CITY, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today announced it plans provide an update on its CNM-Au8 program in ALS, and to host an investor call and webcast at 8:30 am ET on Wednesday, December 3, 2025. The webcast is accessible via the link below or the Investors section of the Company’s website located here.

Webcast Information:
Title: CNM-Au8 ALS Program Update
Presenters: Rob Etherington, CEO and President, Dr. Ben Greenberg, Head of Medical, Michael Hotchkin, Chief Development Officer and a KOL
Date: December 3, 2025
Start Time: 8:30 a.m. ET
Webcast link: https://viavid.webcasts.com/starthere.jsp?ei=1744985&tp_key=9fb9583d33
Dial number: 1-877-407-0779 (US) or 1-201-389-0914 (international), Conference ID#13757380

The archived webcast will be available on the Company's website beginning approximately two hours after the event.

About Clene
Clene Inc., (Nasdaq: CLNN) (along with its subsidiaries, “Clene” and its wholly owned subsidiary Clene Nanomedicine, Inc.), is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis, Parkinson’s disease, and multiple sclerosis. CNM-Au8^® is an investigational first-in-class therapy that improves central nervous system cells’ survival and function via a mechanism that targets mitochondrial function and the NAD pathway while reducing oxidative stress. CNM-Au8^® is a federally registered trademark of Clene Nanomedicine, Inc. The company is based in Salt Lake City, Utah, with R&D and manufacturing operations in Maryland. For more information, please visit www.clene.com or follow us on X (formerly Twitter) and LinkedIn.

About CNM-Au8^®
CNM-Au8 is an oral suspension of gold nanocrystals developed to restore neuronal health and function by increasing energy production and utilization. The catalytically active nanocrystals of CNM-Au8 drive critical cellular energy producing reactions that enable neuroprotection and remyelination by increasing neuronal and glial resilience to disease-relevant stressors. CNM-Au8^® is a federally registered trademark of Clene Nanomedicine, Inc.

Investor Contact
Kevin Gardner
LifeSci Advisors
kgardner@lifesciadvisors.com
617-283-2856

FAQ

When is Clene (CLNN) holding the CNM-Au8 ALS program update webcast?

The webcast is scheduled for December 3, 2025 at 8:30 a.m. ET.

Who are the presenters on the Clene (CLNN) CNM-Au8 ALS investor call on December 3, 2025?

Presenters are Rob Etherington (CEO and President), Dr. Ben Greenberg (Head of Medical), Michael Hotchkin (Chief Development Officer) and a KOL.

How can investors access the Clene (CLNN) CNM-Au8 ALS webcast on December 3, 2025?

Access the live webcast via the company Investors page or the provided webcast link; U.S. dial‑in is 1-877-407-0779 and international is 1-201-389-0914 (Conference ID#13757380).

Will Clene (CLNN) make the CNM-Au8 ALS webcast available after the live event?

Yes, an archived webcast will be available on the company website approximately two hours after the event.

What topic will Clene (CLNN) cover in the December 3, 2025 webcast?

The company will provide an update on its CNM-Au8 program in amyotrophic lateral sclerosis (ALS).